Young boy smiling into the camera

WHO welcomes landmark agreement on first affordable, generic, single-pill HIV treatment regimen containing dolutegravir

21 September 2017 – Global partners announced breakthrough pricing agreement today to enable access to new, high-quality HIV treatment based on dolutegravir. WHO Director-General, Dr. Tedros Adhanom stated, "WHO welcomes this agreement which will make it possible to reach millions of people with better, more affordable and durable HIV drugs. This will save lives for the most vulnerable, bringing the world closer to the elimination of HIV."

Statement on HIV testing services

Statement on HIV testing services

28 August 2017 – HIV testing services are an essential gateway to HIV prevention, treatment, care and support services. WHO and UNAIDS endorse and encourage universal access to knowledge of HIV status. At the end of 2016, approximately 30% of people living with HIV were still unaware of their HIV status. Young people aged 15-24, adult males and people from key populations often have significantly lower access to HIV testing services, are less likely to be linked to treatment and care and have lower levels of viral suppression.

A man promotes HIV/AIDS awareness in Sector-11 of Chandigarh, India, on the eve of World Aids Day.

WHO urges action against HIV drug resistance threat

20 July 2017 – The World Health Organization alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted in several countries. The Organization warns that this growing threat could undermine global progress in treating and preventing HIV infection if early and effective action is not taken.

Pradeep Tewari, Courtesy of Photoshare
WHO at IAS 2017

WHO at IAS 2017

July 2017 - WHO will launch new guidance to ‘fast-track’ the HIV response towards 2020 goals at the 9th IAS Conference on HIV Science in Paris, from 23-26 July. The new publications focus on HIV testing, advanced HIV disease, antiretroviral therapy, HIV drug resistance, service delivery and much more. All information and session flyers are available from the link below.

Children playing on the street

IAS and WHO identify the most critical research needs for infants, children and adolescents living with HIV

23 July 2017 | Paris, France – The most pressing gaps in research needed to improve outcomes for children and adolescents living with HIV are highlighted in the first global priority research agendas on paediatric and adolescent HIV, released at the 9th IAS Conference on HIV Science (IAS 2017) today. The new guidance was developed by the IAS’s Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) and WHO.

Sydelle Willow Smith

WHO prequalifies first HIV self-test and first generic hepatitis C medicine

21 July 2017 – WHO today prequalified the first HIV self-test in a move to increase HIV diagnosis and treatment. The product uses oral fluid as a specimen and provides results in as little as twenty minutes. The move marks a significant step in allowing countries to implement WHO guidelines, released in 2016, recommending HIV self-testing as a complementary approach to reach those who remain undiagnosed due to fear of stigma and discrimination.

Chifundo Mahamba works as a

INSPIRE - major research findings announced

In a supplement to the “Journal of Acquired Immune Deficiency Syndrome (JAIDS)”, published 1 June 2017, WHO shared the key findings of the initiative INSPIRE: Integrating and Scaling up PMTCT through Implementation Research. One key finding highlights the importance and effectiveness of peer support among mothers living with HIV for retention on antiretroviral therapy (ART).

WHO /Zakwathu Communications Malawi, 2016

fact buffet

People living with HIV

36.7 million There were approximately 36.7 million people living with HIV at the end of 2016.

For more: Data and statistics

People on antiretroviral therapy

19.5 millionIn 2016, 19.5 million people living with HIV were receiving ART globally.

For more: HIV/AIDS fact sheet

Mother-to-child transmission

7 out of 107 out of 10 pregnant women living with HIV received antiretroviral treatment.

For more: Data and statistics

In focus: HIV drug resistance

HIV drug resistance develops when people do not adhere to a prescribed treatment plan, often because they do not have consistent access to quality HIV treatment and care. Increasing HIV drug resistance trends could lead to more infections and deaths, and undermine global progress in treating and preventing HIV infection if early and effective action is not taken.


Towards ending AIDS by 2030

Global health sector strategy on HIV, 2016-2021

The Global health sector strategy on HIV, 2016-2021, outlines what countries need to do and what WHO will do to achieve the ambitious target of the 2030 Sustainable Development Agenda.

Stay connected

WHO, Department of HIV

Sign-up for newsletters

Register in our Stakeholders’ database by sending an email to hiv-aids[at] with subject line “Sign-up for newsletters”. You will receive regular updates from our Department.